Item
1.01 Entry into a Material Definitive Agreement.
NaturalShrimp
Incorporated (the “Company”) entered into a securities purchase agreement (the “SPA”) with an investor (the “Investor”)
on August 18, 2021. Although the transaction documents are dated August 17th, they were entered into on August 18th
upon agreement of the Company and the Investor.
Pursuant
to the SPA, the Investor purchased a secured promissory note (the “Note”) in the aggregate principal amount totaling approximately
$5,443,333.33 (the “Principal Amount”). The Note carried an original issue discount totaling $433,333.33 and a transaction
expense amount of $10,000, both of which are included in the principal balance of the Note. The total purchase price of the Note was
$5,000,000. The Note has an interest rate of 12% per annum. The maturity date of the Note is nine (9) months from the issuance date of
the Note (the “Maturity Date”). The Note is not convertible into shares of the Company’s common stock. The Company
intends to use the proceeds from the Note for general working capital purposes.
The
Investor wired $1,100,000 of the purchase price of the Note to the Company and the balance of $3,900,000 (the “Escrow Amount”)
is held in escrow pursuant to an Escrow Agreement dated as of the date of the SPA by and between the Company, the Investor, and Hansen
Black Anderson Ashcraft PLLC and shall be released to the Company, as follows: (a) $500,000 of the Escrow Amount shall be released following
the date that the Company has filed both (i) a Schedule 14C authorizing a reverse stock split in a range of 1:33 to 1:100; and (ii) a
shelf registration statement on Form S-3; and (b) $3,400,000.00 of the Escrow Amount shall be released upon completion of a successful
Uplist (defined below).
The
Company has the option to prepay the Note at any time prior to the Maturity Date by paying a premium of 15% plus the principal, interest,
and fees owed as of the prepayment date.
As
soon as reasonably possible following the issuance of the Note, the Company will cause its common stock to be listed for trading on either
of (a) NYSE, or (b) NASDAQ (in either event, an “Uplist”). In the event the Company has not effectuated the Uplist by November
15, 2022, the then-current outstanding balance will be increased by 10%. The Company will make a one-time payment to the Investor equal
to the greater of (x) $3,000,000 or (y) 33% of the gross proceeds the Company receives from the offering expected to be effected in connection
with the Uplist (whether from the sale of shares of its Common Stock and/or preferred stock) within ten (10) days of receiving such amount.
In the event Borrower does not make this payment, the then-current outstanding balance will be increased by 10%.
The
Note is a secured obligation of the Company, to the extent provided for in the Security Agreement dated as of the date of the SPA (the
“Security Agreement”) entered into by and among the Company and the Investor. The Note shall be senior in right of payment
to all other Indebtedness (as defined in the Note) of the Company subject to the terms set forth in the Security Agreement. The Note
is a direct obligation of the Company issued in accordance with the SPA. The Company granted a first priority security interest in and
to all of the assets of the Company.
The
Note contains certain negative covenants and Events of Default. Upon an Event of a Default, at its option and sole discretion, the Investor
may consider the Note immediately due and payable. Upon such an Event of Default, the interest rate increases to 18% per annum and the
outstanding balance of the Note increases from 5% to 15%, depending upon the specific Event of Default.
Joseph
Gunnar & Co. LLC and Roth Capital Partners LLC served as co-placement agents in connection with the transaction.
The
foregoing descriptions of the SPA, the Note and the Security Agreement are summaries and do not purport to be complete and are qualified
in their entirety by reference to the text of the SPA, the Note, the Escrow Agreement and the Security Agreement, the forms of which
are filed as, respectively, Exhibits 10.1, 4.1, 10.2, and 10.3 hereto.